Critical Success Factors in Patient Safety Strategies
Add bookmarkCritical Success Factors in Patient Safety Strategies
Add bookmark
In this Pharma IQ interview Nabil Al-Tawil, Principal Investigator of the Phase I Unit at Karolinska University Hospital, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase 1 clinical development. Al-Tawil explains the importance of benchmarking the latest strategies to prevent late stage failure and allowing information-rich decisions to be made during early clinical development. He also discusses critical success factors in patient safety strategies, the impact of trial design on patient safety, the trend towards an increased need to include patients already in phase I studies and the main challenges and solutions when using patients in phase I compared to healthy volunteers.
[inlinead]
Tags:
Gabriele Dallmann
Nabil Al-Tawil
phase one
phase I clinical development
phase one clinical trials
Karolinska University Hospital
Pharmatching
patient safety
